Type A meeting completed, next steps pending - Q3 review

Ascelia’s Q3 report showed continued cost control and reduced cash burn, while key focus remains the regulatory path for Orviglance after the FDA’s Type A meeting. Following the results, we update our fair value range to SEK0.2–2.0 (0.3–2.0), with the upper end reflecting a 50% probability of approval, pending further clarity on the prospective SPARKLE analysis and timing.

Q3 review. Ascelia reported no sales and an operating loss of SEK10m (SEK15m in Q3 2025). Operating cash flow was SEK-10m (cSEK-16m in Q3 2025), and cash amounted to SEK28m at quarter-end. Management said the cost-saving measures support a cash runway into Q2 2027.

Little to no new detail in the report following the Type A meeting. The FDA maintains that approval would require additional clinical evidence from a new study. However, Ascelia said the FDA indicated that such evidence could potentially be generated through a prospective reanalysis of Phase 3 SPARKLE images using a different primary endpoint. Our model assumes a material reduction in costs in 2027, but a prospective reanalysis or, particularly a new clinical trial, would create a financing need. We therefore assume an equity raise in 2027, while acknowledging that a potential partnership could provide an alternative funding source.

In our view, the central questions remain whether the FDA will accept the proposed analysis, how long the process will take and what funding it will require. We also await further detail on the European regulatory strategy. For now, the scope, timing and potential implications of this remain unclear.

Estimates and valuation. We make no material changes to our estimates apart from updating for the Q3 numbers. We retain a 20% WACC, reflecting the regulatory, financing and execution risks. The upper end of our SEK0.2–2.0 fair value range reflects a 50% probability of approval.